TY  - JOUR
A1  - Wilhelm, Raphael
A1  - Eckes, Timon Sebastian
A1  - Imre, Gergely
A1  - Kippenberger, Stefan
A1  - Meissner, Markus
A1  - Thomas, Dominique Jeanette
A1  - Trautmann, Sandra
A1  - Merlio, Jean-Philippe
A1  - Chevret, Edith
A1  - Kaufmann, Roland
A1  - Pfeilschifter, Josef
A1  - Koch, Alexander
A1  - Jäger, Manuel Alexander
T1  - C6 ceramide (d18:1/6:0) as a novel treatment of cutaneous T cell lymphoma
T2  - Cancers
N2  - Cutaneous T cell lymphomas (CTCLs) represent a heterogeneous group of T cell lymphomas that primarily affect the skin. The most frequent forms of CTCL are mycosis fungoides and Sézary syndrome. Both are characterized by frequent recurrence, developing chronic conditions and high mortality with a lack of a curative treatment. In this study, we evaluated the effect of short-chain, cell-permeable C6 Ceramide (C6Cer) on CTCL cell lines and keratinocytes. C6Cer significantly reduced cell viability of CTCL cell lines and induced cell death via apoptosis and necrosis. In contrast, primary human keratinocytes and HaCaT keratinocytes were less affected by C6Cer. Both keratinocyte cell lines showed higher expressions of ceramide catabolizing enzymes and HaCaT keratinocytes were able to metabolize C6Cer faster and more efficiently than CTCL cell lines, which might explain the observed protective effects. Along with other existing skin-directed therapies, C6Cer could be a novel well-tolerated drug for the topical treatment of CTCL.
KW  - C6 ceramide
KW  - short-chain ceramide
KW  - cutaneous T cell lymphoma
KW  - skin
Y1  - 2021
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/62479
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-624793
SN  - 2072-6694
N1  - This work was supported by the German Research Foundation (SFB 1039).
VL  - 13
IS  - 2, art. 270
SP  - 1
EP  - 14
PB  - MDPI
CY  - Basel
ER  -